| # | Drug | Count |
|---|---|---|
| 0 | DURVALUMAB | 36 |
| 1 | NIVOLUMAB | 27 |
| 2 | CARBOPLATIN | 26 |
| 3 | PACLITAXEL | 19 |
| 4 | BEVACIZUMAB | 14 |
| 5 | PEMETREXED DISODIUM | 14 |
| 6 | IPILIMUMAB | 13 |
| 7 | TREMELIMUMAB | 13 |
| 8 | ETOPOSIDE | 11 |
| 9 | LANSOPRAZOLE | 8 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIVOLUMAB AND RELATLIMAB-RMBW | 2 | 0.0039 |
| 1 | TREMELIMUMAB | 13 | 0.0029 |
| 2 | DURVALUMAB | 36 | 0.0017 |
| 3 | CEMIPLIMAB-RWLC | 3 | 0.0014 |
| 4 | MEPIVACAINE HYDROCHLORIDE | 1 | 0.0009 |
| 5 | ENFORTUMAB VEDOTIN | 6 | 0.0008 |
| 6 | TALIMOGENE LAHERPAREPVEC | 1 | 0.0006 |
| 7 | SOTORASIB | 2 | 0.0006 |
| 8 | AMPICILLIN SODIUM AND SULBACTAM SODIUM | 1 | 0.0004 |
| 9 | PEMETREXED DISODIUM | 14 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 2 | 0.0039 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 46 | 0.0021 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 181 | 0.0018 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 26 | 0.0005 |
| 4 | Microtubule Inhibitor [EPC] | 25 | 0.0002 |
| 5 | Topoisomerase Inhibitor [EPC] | 11 | 0.0001 |
| 6 | Platinum-based Drug [EPC] | 35 | 0.0001 |
| 7 | Chloride Channel Activator [EPC] | 1 | 0.0001 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 14 | 0.0001 |
| 9 | Dihydrofolate Reductase Inhibitor Antibacterial [EPC] | 4 | 0.0000 |